Regional Variability in MRI Scans with Different Magnetic Field Strengths in Japan: Implications for Healthcare Preparedness for Alzheimer’s Disease Treatment
Abstract
:1. Introduction
2. Materials and Methods
2.1. Database
2.2. Analyses
2.3. Prefectural Characterization
2.4. Ethics
3. Results
3.1. Overall Trends
3.2. Mixed Model Results
3.3. Prefecture Characterization
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Knopman, D.S.; Amieva, H.; Petersen, R.C.; Chételat, G.; Holtzman, D.M.; Hyman, B.T.; Nixon, R.A.; Jones, D.T. Alzheimer disease. Nat. Rev. Dis. Primers 2021, 7, 33. [Google Scholar] [CrossRef] [PubMed]
- Gustavsson, A.; Norton, N.; Fast, T.; Frölich, L.; Georges, J.; Holzapfel, D.; Kirabali, T.; Krolak-Salmon, P.; Rossini, P.M.; Ferretti, M.T.; et al. Global estimates on the number of persons across the Alzheimer’s disease continuum. Alzheimer’s Dement. 2023, 19, 658–670. [Google Scholar] [CrossRef] [PubMed]
- Daigaku, K. Survey on about Pevalence and Future Estimates of Dementia and Mild Cognitive Impairment. Available online: https://www.eph.med.kyushu-u.ac.jp/jpsc/uploads/resmaterials/0000000111.pdf?1715072186 (accessed on 25 July 2024). (In Japanese).
- Jack, C.R., Jr.; Bennett, D.A.; Blennow, K.; Carrillo, M.C.; Dunn, B.; Haeberlein, S.B.; Holtzman, D.M.; Jagust, W.; Jessen, F.; Karlawish, J.; et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement. 2018, 14, 535–562. [Google Scholar] [CrossRef] [PubMed]
- Honig, L.S.; Barakos, J.; Dhadda, S.; Kanekiyo, M.; Reyderman, L.; Irizarry, M.; Kramer, L.D.; Swanson, C.J.; Sabbagh, M. ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer’s disease. Alzheimer’s Dement. 2023, 9, e12377. [Google Scholar] [CrossRef] [PubMed]
- Cummings, J.; Apostolova, L.; Rabinovici, G.D.; Atri, A.; Aisen, P.; Greenberg, S.; Hendrix, S.; Selkoe, D.; Weiner, M.; Petersen, R.C.; et al. Lecanemab: Appropriate Use Recommendations. J. Prev. Alzheimer’s Dis. 2023, 10, 362–377. [Google Scholar] [CrossRef] [PubMed]
- Ministry of Health, Labour, and Welfare. LEQEMBI Optimal Use Guideline. Available online: https://www.mhlw.go.jp/content/12404000/001178607.pdf (accessed on 13 December 2023). (In Japanese)
- Wattjes, M.P.; Lutterbey, G.G.; Harzheim, M.; Gieseke, J.; Träber, F.; Klotz, L.; Klockgether, T.; Schild, H.H. Higher sensitivity in the detection of inflammatory brain lesions in patients with clinically isolated syndromes suggestive of multiple sclerosis using high field MRI: An intraindividual comparison of 1.5 T with 3.0 T. Eur. Radiol. 2006, 16, 2067–2073. [Google Scholar] [CrossRef] [PubMed]
- Cogswell, P.M.; Barakos, J.A.; Barkhof, F.; Benzinger, T.S.; Jack, C.R., Jr.; Poussaint, T.Y.; Raji, C.A.; Ramanan, V.K.; Whitlow, C.T. Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice. AJNR Am. J. Neuroradiol. 2022, 43, E19–E35. [Google Scholar] [CrossRef] [PubMed]
- Mattke, S.; Hlávka, J.P.; Yoong, J.; Wang, M.; Goto, R. Assessing the Preparedness of the Japanese Health Care System Infrastructure for an Alzheimer’s Treatment. 2019. Available online: https://cesr.usc.edu/sites/default/files/Japan_Infrastructure_Report_Update_f2%5B1%5D.pdf (accessed on 9 January 2024).
- Mattke, S.; Loh, W.K.; Yuen, K.H.; Yoong, J. Preparedness of China’s health care system to provide access to a disease-modifying Alzheimer’s treatment. Alzheimer’s Dement. 2023, 19, 5596–5604. [Google Scholar] [CrossRef] [PubMed]
- Brodtmann, A.; Darby, D.; Oboudiyat, C.; Mahoney, C.J.; Le Heron, C.; Panegyres, P.K.; Brew, B. Assessing preparedness for Alzheimer disease-modifying therapies in Australasian health care systems. Med. J. Aust. 2023, 218, 247–249. [Google Scholar] [CrossRef] [PubMed]
- OECD Data. Magnetic Resonance Imaging (MRI) Units. Available online: https://data.oecd.org/healtheqt/magnetic-resonance-imaging-mri-units.htm (accessed on 13 May 2024).
- Ministry of Health, Labour, and Welfare. Deployment and Safety Management of Medical Equipment. Available online: https://www.mhlw.go.jp/file/05-Shingikai-10801000-Iseikyoku-Soumuka/0000130336.pdf (accessed on 13 December 2023). (In Japanese)
- National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB Open Data). Available online: https://www.mhlw.go.jp/ndb/opendatasite/ (accessed on 13 May 2024).
- Sato, K.; Mano, T.; Iwata, A.; Toda, T. Disproportionality by sex in the prescription of drugs capable of inducing parkinsonism for the elderly: A survey using statistics of Japanese national health claims from 2014 to 2017. Neurol. Clin. Neurosci. 2021, 9, 211–217. [Google Scholar] [CrossRef]
- Bates, D.; Maechler, M.; Bolker, B.; Walker, S. Fitting Linear Mixed-Effects Models Using lme4. J. Stat. Softw. 2015, 67, 1–48. [Google Scholar] [CrossRef]
- Ishii, S.; Tanabe, K.; Ishimaru, B.; Kitahara, K. Impact of COVID-19 on Long-Term Care Service Utilization of Older Home-Dwelling Adults in Japan. J. Am. Med. Dir. Assoc. 2023, 24, 156–163.e23. [Google Scholar] [CrossRef] [PubMed]
- McInnes, L.; Healy, J.; Melville, J. Umap: Uniform manifold approximation and projection for dimension reduction. arXiv 2018, arXiv:1802.03426. [Google Scholar]
- Japan Health Policy NOW. Payment System. Available online: https://japanhpn.org/en/finan2/ (accessed on 30 January 2024).
- Ministry of Health, Labour, and Welfare. Establishment and Analysis of a National Clinical Registry of Disease-Modifying Drugs for Alzheimer’s Disease. Available online: https://www.amed.go.jp/koubo/14/03/1403C_00082.html (accessed on 9 June 2024). (In Japanese)
- Saito, N.; Minakawa, S.; Inoue, F.; Kimura, M.; Ogasawara, S.; Kayaba, H. Impact of Geographical Variations on the Prevalence of Multidrug-Resistant Organisms in Japan. Jpn. J. Infect. Dis. 2020, 73, 354–360. [Google Scholar] [CrossRef] [PubMed]
- Biogen. “LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in China. Available online: https://investors.biogen.com/news-releases/news-release-details/leqembir-lecanemab-approved-treatment-alzheimers-disease-china (accessed on 9 January 2024).
- Hosokawa, R.; Ojima, T.; Myojin, T.; Aida, J.; Kondo, K.; Kondo, N. Associations Between Healthcare Resources and Healthy Life Expectancy: A Descriptive Study across Secondary Medical Areas in Japan. Int. J. Environ. Res. Public Health 2020, 17, 6301. [Google Scholar] [CrossRef] [PubMed]
- Sims, J.R.; Zimmer, J.A.; Evans, C.D.; Lu, M.; Ardayfio, P.; Sparks, J.; Wessels, A.M.; Shcherbinin, S.; Wang, H.; Monkul Nery, E.S.; et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 2023, 330, 512–527. [Google Scholar] [CrossRef] [PubMed]
- Food and Drug Administration. FDA Approves Treatment for Adults with Alzheimer’s Disease. Available online: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease (accessed on 2 July 2024).
- Pharma Japan. “Lilly’s Alzheimer’s Med Donanemab Now in Line for Japan Approval. Available online: https://pj.jiho.jp/article/251432 (accessed on 5 August 2024).
Term | Variables | Coefficient | Lower 95% | Upper 95% | ||
---|---|---|---|---|---|---|
Model (1) | exp(β0) | (Intercept) | 0.245 | 0.231 | 0.260 | |
exp(β2) | Field strength of MRI scanner | 1.5T | Reference | |||
<1.5T | 0.252 | 0.211 | 0.302 | |||
3.0T | 0.099 | 0.082 | 0.119 | |||
exp(β1) | Years since FY2015 | 1.000 | 0.993 | 1.006 | ||
exp(β4) | Flag: FY2020 | 0.954 | 0.939 | 0.969 | ||
exp(β3) | Interaction term | Field strength 1.5T × Years | Reference | |||
Field strength < 1.5T × Years | 0.950 | 0.937 | 0.963 | |||
Field strength 3.0T × Years | 1.107 | 1.077 | 1.138 | |||
Model (2) | exp(β0) | (Intercept) | 66.433 | 60.457 | 73.000 | |
exp(β2) | Field strength of MRI scanner | 1.5T | Reference | |||
<1.5T | 0.252 | 0.211 | 0.301 | |||
3.0T | 0.099 | 0.082 | 0.119 | |||
exp(β1) | Years since FY2015 | 1.027 | 1.020 | 1.033 | ||
exp(β4) | Flag: FY2020 | 0.982 | 0.965 | 0.998 | ||
exp(β3) | Interaction term | Field strength 1.5T × Years | Reference | |||
Field strength < 1.5T × Years | 0.950 | 0.937 | 0.963 | |||
Field strength 3.0T × Years | 1.107 | 1.077 | 1.138 | |||
Model (3) | exp(β0) | (Intercept) | 2048.127 | 1937.681 | 2164.868 | |
exp(β2) | Field strength of MRI scanner | 1.5T | Reference | |||
<1.5T | 0.453 | 0.406 | 0.505 | |||
3.0T | 0.528 | 0.450 | 0.620 | |||
exp(β1) | Years since FY2015 | 0.995 | 0.990 | 1.001 | ||
exp(β4) | Flag: FY2020 | 0.951 | 0.937 | 0.966 | ||
exp(β3) | Interaction term | Field strength 1.5T × Years | Reference | |||
Field strength < 1.5T × Years | 1.004 | 0.993 | 1.014 | |||
Field strength 3.0T × Years | 1.043 | 1.020 | 1.066 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sato, K.; Niimi, Y.; Ihara, R.; Iwata, A.; Iwatsubo, T. Regional Variability in MRI Scans with Different Magnetic Field Strengths in Japan: Implications for Healthcare Preparedness for Alzheimer’s Disease Treatment. Biomedicines 2024, 12, 1870. https://doi.org/10.3390/biomedicines12081870
Sato K, Niimi Y, Ihara R, Iwata A, Iwatsubo T. Regional Variability in MRI Scans with Different Magnetic Field Strengths in Japan: Implications for Healthcare Preparedness for Alzheimer’s Disease Treatment. Biomedicines. 2024; 12(8):1870. https://doi.org/10.3390/biomedicines12081870
Chicago/Turabian StyleSato, Kenichiro, Yoshiki Niimi, Ryoko Ihara, Atsushi Iwata, and Takeshi Iwatsubo. 2024. "Regional Variability in MRI Scans with Different Magnetic Field Strengths in Japan: Implications for Healthcare Preparedness for Alzheimer’s Disease Treatment" Biomedicines 12, no. 8: 1870. https://doi.org/10.3390/biomedicines12081870